AbbVie Stock Forecast for 2022 - 2025 - 2030

Updated on 12/02/2022

Stock Rating
7
Price Target
$158.50
Consensus
Outperform
Downside
-1.94%
Analysts
19
Stock Rating
7
Downside
-1.94%
Analysts
19
Price Target
$158.50

AbbVie Stock Forecast and Price Target

AbbVie's stock is projected to advance by -1.94% from the previous closing price if it reaches the average target of $158.50 by the year's end, as nineteen reputable analysts recently projected. This potential downside is calculated on a high-end estimate of $200.00 and a low-end estimate of $120.00. Even if you are not interested in ABBV stock, it is still imperative to be aware of its competitors.

$158.50

-1.94% Downside

Outperform
Outperform

AbbVie Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's Price has grown, increasing from $85.59 to $137.41 – an increase of 60.56%. For next year, the 23 analysts predict Fair Value of $151.59, which would mean an increase of 10.31%. Over the next nine years, the pros' prediction is Fair Valueof $154.94, which would mean a nine-year growth forecast of 12.76%.

2022 Fair Value Forecast
$151.59
2023 Fair Value Forecast
$129.95
2024 Fair Value Forecast
$129.73
2025 Fair Value Forecast
$140.77
2026 Fair Value Forecast
$148.13
2027 Fair Value Forecast
$152.13
2028 Fair Value Forecast
$157.32
2029 Fair Value Forecast
$157.76
2030 Fair Value Forecast
$154.94
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$178.74 $181.36 0.98%
LLY Stock Forecast Eli Lilly and Outperform 16
$370.33 $333.19 5.85%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£112.00 £136.08 28.85%
OR Stock Forecast L'Oréal Hold 18
358.40€ 331.87€ 2.54%
ABT Stock Forecast Abbott Laboratories Outperform 14
$107.93 $128.88 5.62%

AbbVie Revenue Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's Revenue has grown, increasing from $32.75B to $56.20B – an increase of 71.58%. For next year, the 19 analysts predict Revenue of $59.61B, which would mean an increase of 6.07%. Over the next nine years, the pros' prediction is Revenueof $63.93B, which would mean a nine-year growth forecast of 13.76%.

2022 Rev Forecast
$59.61B
2023 Rev Forecast
$55.93B
2024 Rev Forecast
$56.47B
2025 Rev Forecast
$58.95B
2026 Rev Forecast
$61.80B
2027 Rev Forecast
$63.60B
2028 Rev Forecast
$65.34B
2029 Rev Forecast
$65.24B
2030 Rev Forecast
$63.93B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$80.88 $79.05 2.50%
AMGN Stock Forecast Amgen Hold 7
$285.94 $246.51 -9.77%
ABI Stock Forecast Anheuser-Busch InBev SA/NV Outperform 18
56.89€ 76.71€ 13.85%

AbbVie Dividend per Share Forecast for 2022 - 2025 - 2030

AbbVie's Dividend per Share has increased by 34.43% In the last three years, going from $3.95 to $5.31. In the next year, analysts expect Dividend per Share to reach $5.71 – an increase of 7.53%. For the next nine years, the forecast is for Dividend per Share to grow by 15.44%.

2022 DPS Forecast
$5.71
2023 DPS Forecast
$6.00
2024 DPS Forecast
$6.17
2025 DPS Forecast
$6.50
2026 DPS Forecast
$6.93
2027 DPS Forecast
$6.79
2028 DPS Forecast
$6.13
2029 DPS Forecast
$6.13
2030 DPS Forecast
$6.13
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Outperform 9
$87.90 $69.65 -7.85%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$250.83 $272.08 8.04%
GSK Stock Forecast GSK Outperform 16
£14.15 £16.08 14.13%

AbbVie Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's Free Cash Flow has grown by 71.94%, from $12.79B to $21.99B. For the next year, analysts are expecting Free Cash Flow to reach $23.98B – an increase of 9.04%. Over the next nine years, experts predict that Free Cash Flow will grow by 26.59%.

2022 FCF Forecast
$23.98B
2023 FCF Forecast
$23.54B
2024 FCF Forecast
$22.89B
2025 FCF Forecast
$24.83B
2026 FCF Forecast
$26.28B
2027 FCF Forecast
$27.04B
2028 FCF Forecast
$27.44B
2029 FCF Forecast
$27.33B
2030 FCF Forecast
$27.84B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MMM Stock Forecast 3M Hold 16
$125.99 $147.79 1.20%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.60k ¥0.00 13.12%
BAYN Stock Forecast Bayer Outperform 7
55.03€ 67.79€ 43.56%

AbbVie Net Income Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's Net Income has grown, increasing from $5.69B to $11.54B – a growth of 102.95%. The next year looks promising for AbbVie, with analysts predicting Net Income of $24.99B – an increase of 116.56%. Over the next nine years, experts anticipate that AbbVie's Net Income will grow at a rate of 106.60%.

2022 NI Forecast
$24.99B
2023 NI Forecast
$21.29B
2024 NI Forecast
$21.25B
2025 NI Forecast
$22.87B
2026 NI Forecast
$23.91B
2027 NI Forecast
$24.17B
2028 NI Forecast
$24.72B
2029 NI Forecast
$24.54B
2030 NI Forecast
$23.85B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.66k ¥0.00 23.09%
BIIB Stock Forecast Biogen Outperform 11
$301.85 $242.78 7.67%
ALC Stock Forecast Alcon Outperform 15
CHF65.48 CHF0.00 29.15%

AbbVie EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's EBITDA has grown from $13.69B to $28.05B – a 104.92% increase. Next year, analysts are expecting EBITDA to reach $31.73B – an increase of 13.12%. Over the next nine years, the forecast is for EBITDA to grow by 13.19%.

2022 EBITDA Forecast
$31.73B
2023 EBITDA Forecast
$27.70B
2024 EBITDA Forecast
$27.42B
2025 EBITDA Forecast
$28.53B
2026 EBITDA Forecast
$31.22B
2027 EBITDA Forecast
$31.94B
2028 EBITDA Forecast
$33.00B
2029 EBITDA Forecast
$32.39B
2030 EBITDA Forecast
$31.75B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GMAB Stock Forecast Genmab A/S Outperform 16
kr3.30k kr2.84k -16.54%
4503 Stock Forecast Astellas Pharma Outperform 18
¥2.13k ¥0.00 12.83%
BAX Stock Forecast Baxter International Outperform 17
$52.38 $65.40 22.18%

AbbVie EBIT Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's EBIT has grown by 63.79%, rising from $11.92B to $19.53B. For next year, analysts predict EBIT of $30.79B, which would mean an increase of 57.65%. Over the next nine years, experts predict that AbbVie's EBIT will grow at a rate of 60.72%.

2022 EBIT Forecast
$30.79B
2023 EBIT Forecast
$26.78B
2024 EBIT Forecast
$26.64B
2025 EBIT Forecast
$28.40B
2026 EBIT Forecast
$30.12B
2027 EBIT Forecast
$31.25B
2028 EBIT Forecast
$32.46B
2029 EBIT Forecast
$32.42B
2030 EBIT Forecast
$31.39B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BEI Stock Forecast Beiersdorf Outperform 17
105.65€ 102.71€ 6.01%
HZNP Stock Forecast Horizon Therapeutics Public Buy 16
$100.88 $0.00 38.78%
4523 Stock Forecast Eisai Hold 18
¥9.78k ¥0.00 -32.48%

AbbVie EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's EPS has grown, increasing from $7.91 to $12.70 – an increase of 60.56%. For next year, the 23 analysts predict EPS of $14.01, which would mean an increase of 10.31%. Over the next nine years, the pros' prediction is EPSof $14.32, which would mean a nine-year growth forecast of 12.76%.

2022 EPS Forecast
$14.01
2023 EPS Forecast
$12.01
2024 EPS Forecast
$11.99
2025 EPS Forecast
$13.01
2026 EPS Forecast
$13.69
2027 EPS Forecast
$14.06
2028 EPS Forecast
$14.54
2029 EPS Forecast
$14.58
2030 EPS Forecast
$14.32
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$103.02 $113.64 10.66%
4452 Stock Forecast Kao Outperform 18
¥5.46k ¥0.00 9.91%
INCY Stock Forecast Incyte Outperform 9
$80.68 $95.69 1.64%